Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Down 6.38%
As of Wednesday, July 29, ORIC Pharmaceuticals, Inc.’s ORIC share price has dipped by 6.38%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 10.24%
As of Friday, July 24, ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 10.24%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 11.48%
As of Friday, July 24, ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 11.48%, which has investors questioning if this is right time to sell.Omar Beirat
Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 5.41%
As of Thursday, June 25, ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 5.41%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ORIC Pharmaceuticals, Inc.’s (ORIC) Stock Is Up 6.29%
As of Wednesday, June 24, ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 6.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ORIC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,143.9 | $252.6 | 47% |
|
| Shares Out (Mil) | 105.5 | 52.3 | 63% |
|
| Institutional Ownership | 98.9% | 92.1% | 83% |
|
| Float (Mil) | 82.7 | 40.2 | 58% |
|
| Beta | 1.10 | 0.95 | 65% |
|
| Avg Daily Volume (000s) | 1,678 | 455 | 79% |
|
| Price Change (52-week) |
3.2% | 52.9% | 48% |
|
| Growth | ORIC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (11.9%) | (9.9%) | 27% |
|
| EPS (5yr) | 15.2% | 16.0% | 57 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 20.1% | (15.6%) | 79% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 11 | |
| Current EPS | ($0.361) | ($1.468) | ($1.615) | |
| Month Ago EPS | ($0.361) | ($1.468) | ($1.605) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.343) | ($1.403) | ($1.548) | |
| Year/Year Chg | 6.5% | (0.5%) | 18.6% | |
| Financials | ORIC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($135) | ($43) | 9% |
|
| EPS (TTM) | ($1.403) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($111) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $5 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $5 | 23% |
|
| Enterprise Value (Q1) (Mil) | $716 | $180 | 38% |
|
| Valuation | ORIC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.75 | 2.56 | 62% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ORIC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (39.8%) | (49.8%) | 14% |
|
| ROE | (42.6%) | (55.5%) | 17% |
|
| Liabilities to Assets | 4.9% | 30.3% | 2% |
|
| F-Score | 4 | 3 | 34% |
|
ORIC Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
